Home / Market News / $EVMN

$EVMN news and market catalysts

The 8 most recent market catalysts affecting $EVMN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

8 catalysts 1 high impact 1 bullish 4 bearish Biotechnology
Oct 12, 2026 Corporate Catalyst Neutral Impact 55
UBS Initiates Coverage On Evommune with Neutral Rating, Announces Price Target of $8
UBS analyst Alice Nettleton initiated coverage on Evommune (EVMN) with a Neutral rating and an $8 price target. This is a significant event for Evommune as it marks the entry of a …
Oct 1, 2026 Corporate Catalyst Bullish Impact 75
Evommune Presents Additional Data From Phase 2a Proof-Of-Concept Trial Of EVO301 In Adults With Atopic Dermatitis At EADV 2026 Congress; Plan To Initiate Subcutaneous Phase 2b Dose-Ranging Trial In Mid-2027
Evommune announced additional positive data from its Phase 2a trial of EVO301 for atopic dermatitis, presented at EADV 2026. The data highlighted a strong therapeutic signal, favor…
Sep 23, 2026 Corporate Catalyst Neutral Impact 65
Evommune To Present Results From Phase 2a Study Of EVO301 In Moderate-To-Severe Atopic Dermatitis At European Academy Of Dermatology & Venereology Congress
Evommune, a clinical-stage biotechnology company, has announced that it will present Phase 2a trial results for its drug candidate, EVO301, at a major medical conference in 2026. T…
Sep 9, 2026 Corporate Catalyst Bearish Impact 55
Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22
Leerink Partners maintaining an 'Outperform' rating suggests a continued belief in Evommune's fundamental strength and future growth potential. However, the reduction in the price …
Sep 9, 2026 Corporate Catalyst Bearish Impact 65
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21
RBC Capital's analyst Brian Abrahams maintained an 'Outperform' rating on Evommune, signaling continued confidence in the company's fundamentals or future potential. However, the s…
Sep 9, 2026 Corporate Catalyst Bearish Impact 85
Evommune Halts Atopic Dermatitis Program Following Trial Failure
Evommune's EVO756 failed to meet primary and secondary endpoints in its Phase 2b trial for atopic dermatitis, leading the company to halt development for this indication. This is a…
Aug 26, 2026 Corporate Catalyst Neutral Impact 65
Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28
Needham analyst Serge Belanger has initiated coverage on Evommune (EVMN) with a 'Buy' rating and a $28 price target. This event is significant for EVMN as it introduces a new insti…
Aug 7, 2026 Corporate Catalyst Bearish Impact 55
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $29
RBC Capital analyst Brian Abrahams maintained an 'Outperform' rating on Evommune, signaling continued confidence in the company's fundamentals and future performance. However, the …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.